Home » Business News » 2012 » March » March 20, 2012

Ablynx Announces an Extension of Its Global Strategic Nanobody Alliance With Boehringer Ingelheim

March 20, 2012 - Ghent, Belgium

Ablynx (Euronext Brussels: ABLX) today announceda two-year extension of the initial five-year research funding byBoehringerIngelheim of their global strategic alliance to discover, developandcommercialise up to 10 different Nanobody(®) therapeutics. Theextension whichwill run until September 2014, will allow all the existing tenNanobodyprogrammes to advance to a stage where Boehringer Ingelheim canpotentiallyprogress each programme into development. Ablynx will receive a total ofEUR6.6million in additional research funding from Boehringer Ingelheim, some ofwhichwill be in advance. This payment is in return for work carried out byAblynx'sspecialist Nanobody scientists. Ablynx has already received over EUR58millionfrom payments under the Strategic Alliance since it was signed in 2007.

In September 2007, Ablynx and Boehringer Ingelheim entered into aStrategicAlliance on the discovery, development and commercialisation ofNanobodytherapeutics across a range of diseases, including oncology,immunology, andrespiratory diseases. The agreement allows for potential milestonepayments ofup to EUR125 million plus royalties to Ablynx for each Nanobody whichreachesmarket. Boehringer Ingelheim is exclusively responsible for thedevelopment,manufacturing and commercialisation of any products resulting fromthecollaboration. Ablynx retains certain co-promotion rights in Europe.

Dr Edwin Moses, CEO and Chairman of Ablynx, said:

"We are delighted to extend the current Strategic Alliance. As a result ofthisvery successful collaboration, there are now two Nanobody programmesalready inpre-clinical development and seven Nanobodies at various stages indiscoveryacross multiple disease areas. In addition, as part of a separatecollaborationwith Boehringer Ingelheim, there is a Nanobody relevant in Alzheimer'sdiseasealso at the pre-clinical development stage. We are very pleased to haveelevenNanobody programmes potentially able to make an importantcontribution toBoehringer Ingelheim's R&D pipeline."

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery anddevelopmentof Nanobodies(®), a novel class of therapeutic proteins based onsingle-domainantibody fragments, for a range of serious and life-threatening humandiseases,including inflammation, haematology, oncology and pulmonary disease.Today, theCompany has over 25 programmes in the pipeline and seven Nanobodies atclinicaldevelopment stage. Ablynx has ongoing research collaborations andsignificantpartnerships with major pharmaceutical companies, includingBoehringerIngelheim, Merck Serono and Novartis. The Company is headquartered inGhent,Belgium. More information can be found on

Complete version of the press release:

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE[HUG#1595865]

For more information, please contact

Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: Email Contact

Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: Email Contact

Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: Email Contact


Comment on this story